This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

This study has been completed.
Information provided by:
Solvay Pharmaceuticals Identifier:
First received: August 1, 2005
Last updated: January 15, 2015
Last verified: March 2006
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in male patients.

Condition Intervention Phase
Atrial Fibrillation Atrial Flutter Drug: Tedisamil sesquifumarate Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibrillation or Flutter

Resource links provided by NLM:

Further study details as provided by Solvay Pharmaceuticals:

Study Start Date: October 2004
Study Completion Date: January 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing to sign informed consent before screening examinations are performed and before the study drug is administered
  • Males > 18 years of age
  • Subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration > 3 hours and < 45 days) at the time of randomization
  • Subjects who are in no distress and hemodynamically stable (supine systolic blood pressure > 90 mmHg and diastolic blood pressure < 105 mmHg)

Exclusion Criteria:

  • Acute myocardial infarction and cerebrovascular accidents
  • Coronary and heart failure symptoms
  • Life-threatening ventricular arrhythmias and electrocardiogram (ECG) abnormalities
  • Electrolyte abnormalities
  • Concurrent antiarrhythmic treatments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00126061

United States, California
Site 26
Los Angeles, California, United States
Site 27
Santa Ana, California, United States
United States, Hawaii
Site 24
Honolulu, Hawaii, United States
United States, Tennessee
Site 25
Tullahoma, Tennessee, United States
Czech Republic
Site 5
Brno, Czech Republic
Site 4
Plzen, Czech Republic
Site 2
Prague, Czech Republic
Site 3
Prague, Czech Republic
Site 6
Prague, Czech Republic
Site 8
Bydgoszcz, Poland
Site 11
Lodz, Poland
Site 10
Lublin, Poland
Site 12
Medyczna, Poland
Site 7
Warszawa, Poland
Site 9
Warszawa, Poland
Russian Federation
Site 13
Moscow, Russian Federation
Site 14
Moscow, Russian Federation
Site 15
Moscow, Russian Federation
Site 16
Moscow, Russian Federation
Site 17
Moscow, Russian Federation
Site 20
Dnepropetrovsk, Ukraine
Site 18
Kiev, Ukraine
Site 21
Kiev, Ukraine
Site 19
Lviv, Ukraine
Site 23
Odessa, Ukraine
Site 22
Zaporozhye, Ukraine
Sponsors and Collaborators
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
  More Information Identifier: NCT00126061     History of Changes
Other Study ID Numbers: S219.3.117
Study First Received: August 1, 2005
Last Updated: January 15, 2015

Keywords provided by Solvay Pharmaceuticals:
Atrial fibrillation
atrial flutter
anti-arrhythmic agents
conversion to normal sinus rhythm

Additional relevant MeSH terms:
Atrial Fibrillation
Atrial Flutter
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Anti-Arrhythmia Agents
Cardiotonic Agents
Protective Agents
Physiological Effects of Drugs processed this record on August 18, 2017